HOME > TOP STORIES

TOP STORIES

BUSINESS Nippon Express to Set Up 4 Distribution Centers for Full-Scale Drug Logistics Biz, Aims for 15 Billion Yen Annual Sales

January 29, 2019
BUSINESS Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show

January 28, 2019
BUSINESS Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing

January 25, 2019
REGULATORY MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo

January 24, 2019
BUSINESS Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief

January 22, 2019
BUSINESS Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing

January 21, 2019
BUSINESS Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment

January 18, 2019
REGULATORY PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan

January 17, 2019
REGULATORY MHLW Won’t Necessarily Push March Announcement of New Drug Prices: Bureau Head

January 16, 2019
BUSINESS Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise

January 15, 2019
REGULATORY PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection

January 15, 2019
COMMENTARY 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals

January 11, 2019
REGULATORY MHLW to Revise Biosimilar Guidelines to Increase Efficiency in Development, Review; Final Draft Expected in FY2019

January 10, 2019
REGULATORY MHLW Approves Amgen/Astellas’ Evenity, Gilead Sciences’ Epclusa and More

January 9, 2019
BUSINESS Takeda Completes £46 Billion Shire Acquisition

January 8, 2019
REGULATORY MHLW to Follow Up on Drug Makers’ Efforts to Observe New Detailing Guidelines

January 7, 2019
BUSINESS Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?

January 4, 2019
BUSINESS Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan

December 28, 2018
BUSINESS Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline

December 27, 2018
TRENDS Top 10 PHARMA JAPAN Stories in 2018

December 26, 2018

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…